Cencora’s FormularyDecisions Introduces Payer Resource for Cell and Gene Therapy Products

Amidst the growing landscape of cell and gene therapy (CGT) products in clinical development, Cencora’s FormularyDecisions has unveiled a new resource tailored to offer healthcare payers centralized access to information on approved therapies and those in the pipeline. FormularyDecisions, a…

Read MoreCencora’s FormularyDecisions Introduces Payer Resource for Cell and Gene Therapy Products

HCA Healthcare Allocates $100 Million in Grants from the HCA Healthcare Hope Fund to Assist Needy Colleagues

HCA Healthcare, Inc. (NYSE:HCA), a prominent healthcare provider in the United States, has announced that its HCA Healthcare Hope Fund, a 501(c)3 public charity offering emergency aid to colleagues facing significant hardships such as illness, injury, natural disasters, or other…

Read MoreHCA Healthcare Allocates $100 Million in Grants from the HCA Healthcare Hope Fund to Assist Needy Colleagues

Forecast 2023-2028: Strong Growth Expected in Global Fetal Doppler Market Driven by Increased At-Home Utilization and Technological Advancements

The ResearchAndMarkets.com platform now includes the “Fetal Doppler Market – Global Outlook & Forecast 2023-2028” report in its offerings. The global fetal Doppler market is poised for significant advancement driven by heightened at-home usage, integration with mobile apps, and a…

Read MoreForecast 2023-2028: Strong Growth Expected in Global Fetal Doppler Market Driven by Increased At-Home Utilization and Technological Advancements

Viz.ai Corrects and Replaces Announcement: Viz™ Neuro Suite’s Impact on Patient Care Validated by Six Clinical Studies

The second sentence of the first paragraph of the release should read: “Six studies, presented at the International Stroke Conference (ISC) 2024, have shown positive outcomes with real-world impact of Viz.ai in clinical practice across various neurology pathologies including acute…

Read MoreViz.ai Corrects and Replaces Announcement: Viz™ Neuro Suite’s Impact on Patient Care Validated by Six Clinical Studies

Delta-Fly Pharma Inc. Submits Abstracts for Phase I Clinical Trial of DFP-14927 to the 2024 ASCO Annual Meeting

Following our previous update on January 5, 2024, we are delighted to share the latest advancements with you. A Phase I dose-ranging clinical trial investigating DFP-14927 in patients with solid tumors has been successfully conducted at MD Anderson Cancer Center…

Read MoreDelta-Fly Pharma Inc. Submits Abstracts for Phase I Clinical Trial of DFP-14927 to the 2024 ASCO Annual Meeting

Enanta Pharmaceuticals Announces Fiscal First Quarter Financial Results for December 31, 2023, Hosting Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology firm specializing in small molecule drugs within virology and immunology, has released its financial results for the fiscal first quarter ending December 31, 2023. The company’s President and Chief Executive Officer, Jay…

Read MoreEnanta Pharmaceuticals Announces Fiscal First Quarter Financial Results for December 31, 2023, Hosting Webcast and Conference Call Today at 4:30 p.m. ET

Healthmine Welcomes Maureen Sullivan, Former Executive at Blue Cross Blue Shield Association, to Advisory Board

Healthmine Welcomes Maureen Sullivan, Former Chief Strategy and Innovation Officer at Blue Cross Blue Shield Association, to Advisory Board Healthmine, a pioneer in technology-driven member engagement solutions, proudly announces the addition of Maureen Sullivan, President of Balestrand Strategic Advisors, to…

Read MoreHealthmine Welcomes Maureen Sullivan, Former Executive at Blue Cross Blue Shield Association, to Advisory Board